Abstract 1285A: Erythropoietin can cancelchemo-resistances viadown regulation of ABC transporters

Abstract

Introduction: Erythropoietin (EPO) is a glycoprotein cytokine which stimulates red blood cell production (erythropoiesis) in the bone marrow. The receptor of it (EPOR) was reported to exist on the cancer cellular membrane: more than 85% cancer cell expresses EPOR. Several reports suggested to play an important role for cancer cellular growth, however, the role of EPOR in cancer cells is not confirmed. The authors have studied the cancer cellular porphyrin accumulation, metabolism and excretion to clear the pathogenetic mechanism which involved the high concentration of porphyrins. The authors found that reactive oxygen species (ROS) accelerate both the cancer cellular porphyrin accumulation and the effect of photodynamic therapy. However, we cannot confirm which substrate is a key of signal transduction. EPO has been known used to be up-regulated at the metabolic acidosis via the stabilization of HIF-1α, a nuclear factor. Since HIF-1α can be stabilized by not only acidosis but also the high concentration of nitric oxide (NO), NO rich cancer cells may involve EPOR. Moreover, the purpose of EPO-EPOR system is likely to survive the hypoxic condition, it may keep intracellular heme/ porphyrins. The authors’ hypothesis is EPO-EPOR system in cancer cells may down-regulate ABCG2 which excretes heme/ porphyrins, and several anti-cancer drugs. Moreover, if so, the excretion of several anti-cancer chemo reagents should be inhibited to involve more effective chemotherapy. Methods: To prove these possibilities, the authors carry out following experiments with gastric and colorectal cancer cells. The existence of EPOR, the amount of ABC transporters (B1, C5, G2) after the recombinant EPO (rEPO) exposure (dose dependency and time dependency) were analyzed by western blotting. Cytotoxicity of anti-cancer drugs with or without rEPO was measured with the Cell Counting Kit-8. Result: (1) EPOR existed in each cell line used in this study. (2) rEPO treatment involved down regulation of ABC transporters (B1, C5, G2) in dose dependently. (3) ABCG2 expression decreased until 24 hours after rEPO treatment. However, its expression re-increased 48 hours after treatment. (4) The 24 hours pretreatment of EPO significantly increased the effect of doxorubicin, paclitaxel, irrinotecan, cisplatin, 5-FU and oxaliplatin even in chemo-resistant cells. Conclusions: rEPO accelerates the effect of anti-cancer drugs via the down regulation of ABC transporters. Citation Format: Hirofumi Matsui, Hiromi Kurokawa. Erythropoietin can cancelchemo-resistances viadown regulation of ABC transporters [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1285A.